StoxPiramal Pharma vs Krishna Institute of Medical Sciences: share price & financials comparison
NSE: PPLPHARMA vs KIMS · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Piramal Pharma vs Krishna Institute of Medical Sciences at a glance
Piramal Pharma (PPLPHARMA) has a market capitalisation of ₹31,791 Cr, against ₹30,366 Cr for Krishna Institute of Medical Sciences (KIMS). Over the past year Piramal Pharma has returned +17.2%, compared with -1.7% for Krishna Institute of Medical Sciences. Krishna Institute of Medical Sciences earns a higher return on equity (5.4% vs -2.6%). Piramal Pharma comes out ahead on financial health, momentum and technicals. Krishna Institute of Medical Sciences comes out ahead on size, profitability and growth. Across the scored metrics below, Piramal Pharma leads on 7 and Krishna Institute of Medical Sciences on 7. On StoxGud's 10-point checklist, Piramal Pharma scores 6/10 and Krishna Institute of Medical Sciences scores 4/10.
| Metric | Piramal Pharma | Krishna Institute of Medical Sciences |
|---|---|---|
| Size | ||
| Market cap | ₹31,791 Cr | ₹30,366 Cr |
| Revenue (latest FY) | ₹8,869 Cr | ₹3,905 Cr |
| Net profit (latest FY) | ₹-326 Cr | ₹241 Cr |
| Valuation | ||
| P/E | — | 143.0 |
| P/B | 3.90 | 7.72 |
| Dividend yield | 0.06% | 0.68% |
| Profitability | ||
| Return on equity | -2.6% | 5.4% |
| Net profit margin | -2.1% | 4.6% |
| Operating margin | 12.3% | 19.3% |
| Growth | ||
| Revenue growth (YoY) | +28.1% | +39.9% |
| Net profit growth (YoY) | — | +11.8% |
| Revenue CAGR (multi-year) | +7.8% | +24.0% |
| Financial health | ||
| Debt to equity | 0.70 | 0.90 |
| Momentum | ||
| 1-month return | +17.9% | +4.2% |
| 1-year return | +17.2% | -1.7% |
| 3-year CAGR | +30.2% | +24.8% |
| 5-year CAGR | — | +25.3% |
| Distance from 52W high | -0.3% | -15.0% |
| Technicals | ||
| RSI (14) | 76 | 66 |
| Price vs 200-day avg | +33.9% | -0.7% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Piramal Pharma | Krishna Institute of Medical Sciences |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 6/10 | 4/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Piramal Pharma or Krishna Institute of Medical Sciences?
Piramal Pharma has a market cap of ₹31,791 Cr and Krishna Institute of Medical Sciences has a market cap of ₹30,366 Cr as of 06 Nov 2026.
Which gave better returns in the last year, Piramal Pharma or Krishna Institute of Medical Sciences?
Piramal Pharma did better: Piramal Pharma returned +17.2% and Krishna Institute of Medical Sciences returned -1.7% over one year.
Is Piramal Pharma or Krishna Institute of Medical Sciences a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Piramal Pharma scores 6/10 and Krishna Institute of Medical Sciences scores 4/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.